Comparison of prostate cancer cell line growth in fetal bovine serum and animal free supplements
Itting E., Wingren AG., Tassidis H.
Animal Study, published in Mol Biol Rep (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Biol Rep (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41410811
- PMCID
- PMC12715057
- DOI
- 10.1007/s11033-025-11362-w
Abstract (original English)
Fetal bovine serum (FBS) is widely used as a growth supplement in cell culture due to its richness in embryonic growth-promoting factors, but presents ethical concerns, batch-to-batch variability, high cost, and biosafety issues. Alternative supplements are needed to support consistent and reliable cell growth in vitro. Human platelet lysate (hPL) and chemically defined supplements offer potential substitutes, but they require evaluation across different cell types. This study aimed to evaluate the effectiveness of two commercial serum supplements, PLTGold (an hPL product) and FastGro (a chemically defined supplement), as alternatives to FBS for supporting the growth and proliferation of the prostate cancer cell lines PC-3 and LNCaP. These cell lines were cultured in media supplemented with different concentrations of FBS, PLTGold, or FastGro. Cell viability was assessed using the MTT assay after 3, 4, and 7 days. Cell cycle distribution was analyzed using propidium iodide staining and flow cytometry after 3 days of culture. Finally, BrdU incorporation assays were conducted to evaluate cell proliferation. Interestingly, PLTGold demonstrated cell viability comparable to or even greater than FBS in PC-3 cells and maintained LNCaP viability, whereas FastGro reduced the viability in both cell lines. FastGro-induced cell cycle arrest was observed in PC-3 cells, indicating a more pro
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.